Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INCR
HOLDInterCure Ltd. · Healthcare · Israel · $55M · Avg Vol: $19K/d
36
StockRankGet insider-trade alerts
Q
37
V
53
M
37
P/E (TTM)
—
ROE
-9.3%
D/E
0.5x
Dividend %
—
COMPANY DESCRIPTION
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 128.5M | 117.5M | 78.9M | 89.3M | -11.4% | 90.1M |
| EPS | 0.04 | 0.33 | -0.45 | -0.49 | -0.22 | 725.0% | -0.22 |
| Shares | — | 45.6M | 45.6M | 47.2M | 54.7M | +20.0% | 59.2M |
| Debt | — | 84.3M | 64.7M | 69.9M | 60.5M | -10.5% | 61.0M |
| Equity | — | 165.7M | 150.4M | 131.2M | 131.1M | -7.5% | — |
| Op CF | — | 16.9M | -17.7M | -22.1M | 5.6M | -31.0% | 5.6M |
| Inv CF | — | -47.1M | 1.6M | 5.8M | -0.7M | — | — |
| Fin CF | — | 39.8M | -27.4M | 8.7M | -15.4M | — | — |
Loading 1Y...
PRICE (1Y)-7.5%
SMA 50SMA 200
Close
$0.96
RSI (14)
56.6
52W High
$1.77
From 52W High
0.5%
SCORE BREAKDOWN
Quality
37
ROIC
-5.1%40.7
ROE
-9.3%37.5
GP/Assets
4.8%19.4
Op. Margin
0.0%40.9
FCF/Assets
1.9%55.0
Piotroski
549.9
Int. Cover
-1.2x34.9
D/E Ratio
0.46x32.0
Current Ratio
1.48x25.7
Value
53
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
12.5x77.0
P/B
0.4x98.6
P/S
0.6x90.1
Div Yield
—N/A
Momentum
37
52W High %
54%26.7
RS 6M
-4%62.4
SMA 50/200
0.98x59.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-573%1.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$55M
P/E (Forward)
-0.6x
Gross Margin
15.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCR | InterCure Ltd.(you) | $55M | 36 | HOLD |
| KMDA | Kamada Ltd. | $407M | 83 | STRONG BUY |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
| PYPD | PolyPid Ltd. | $75M | 21 | SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| NNOX | Nano-X Imaging Ltd. | $62M | 8 | STRONG SELL |
| ENTX | Entera Bio Ltd. | $101M | 17 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| TEVA | Teva Pharmaceutical Industries Limited | $35.9B | 69 | BUY |
Peer medians: ROE 5.1% · P/E 16.5x · Gross margin 36.8%